Form 4: Precision BioSciences GC Sells Shares After RSU Vesting

Precision BioSciences General Counsel Dario Scimeca sold 665 shares of common stock for tax purposes following the vesting of 1,835 Restricted Stock Units.

Summary

• Dario Scimeca, General Counsel and Secretary of Precision BioSciences Inc. (DTIL), reported transactions involving the company's common stock.
• On November 2, 2025, 1,835 Restricted Stock Units (RSUs) vested, representing a contingent right to receive one share of common stock per RSU.
• These RSUs were granted on November 2, 2022, and vested in three substantially equal annual installments, with full vesting occurring on November 2, 2025.
• Following the vesting, Scimeca beneficially owned 28,923 shares of common stock.
• On November 3, 2025, Scimeca sold 665 shares of common stock at a price of $6.49 per share.
• The sale was executed pursuant to a Rule 10b5-1 plan adopted on September 29, 2025, and was solely a 'sell-to-cover' transaction to satisfy tax withholding obligations related to the RSU vesting.
• After the sale, Scimeca beneficially owns 28,258 shares of common stock.
• The reported beneficial ownership also includes 2,088 shares acquired under the Issuer's 2019 Employee Stock Purchase Plan at a weighted average price of $4.26.

Sentiment

Score: 5

Explanation: The filing reports a routine insider transaction involving RSU vesting and a subsequent sell-to-cover for tax purposes. This is a neutral event, common for executives receiving equity compensation, and does not indicate significant positive or negative sentiment regarding the company's performance or outlook.

Positives

• The vesting of 1,835 Restricted Stock Units indicates continued executive compensation and retention, aligning management interests with shareholders.
• The transaction was conducted under a pre-arranged Rule 10b5-1 plan, demonstrating a structured approach to insider trading compliance.

Negatives

• A reduction in direct insider ownership, even if for tax purposes, slightly decreases the total shares held by a key executive.

Future Outlook

NA

Management Comments

• The sales were effected pursuant to a Rule 10b5-1 plan adopted on September 29, 2025.
• The transaction was a sell-to-cover, with shares only sold to cover tax withholding obligations in connection with the vesting and settlement of RSUs.
• The Reporting Person did not sell or otherwise dispose of shares reported on this Form 4 for any reason other than to cover required taxes and fees.

Industry Context

This Form 4 filing reports a routine insider transaction (vesting and tax-related sale) for an executive at a biotechnology company. Such transactions are common across all industries for executives receiving equity compensation.

Comparison to Industry Standards

• The use of a Rule 10b5-1 plan for the sale of shares is a standard practice among executives to comply with insider trading regulations and avoid accusations of trading on material non-public information.
• Sell-to-cover transactions for tax obligations upon RSU vesting are a common and expected event for executives receiving equity compensation in publicly traded companies, aligning with typical compensation structures in the biotech and broader corporate sectors.

Corporate Governance

Stakeholder Impact

• Shareholders: A minor reduction in direct insider ownership, though the transaction's purpose (tax coverage) is routine and generally not viewed negatively.
• Employees: The vesting of RSUs for a key executive reinforces the company's equity compensation structure, which can be a positive for employee retention and motivation.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction where an executive's Restricted Stock Units vested, followed by a 'sell-to-cover' sale to satisfy tax obligations. Such transactions are common and pre-arranged under a Rule 10b5-1 plan, indicating compliance and a lack of discretionary trading based on new information. The filing does not provide new material information about the company's operational performance, financial health, or strategic direction that would warrant a change in investment thesis. Therefore, a 'hold' recommendation is appropriate, as this specific event is neutral in its impact on the company's fundamental value.

Keywords

DTIL, Precision BioSciences, Insider Trading, Form 4, Restricted Stock Units, RSU Vesting, Executive Compensation, Stock Sale, Rule 10b5-1 Plan